SNYNF (Sanofi) Total Liabilities : $61,096 Mil (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sanofi Total Liabilities?

Sanofi's Total Liabilities for the quarter that ended in Jun. 2024 was $61,096 Mil.

Sanofi's quarterly Total Liabilities increased from Jun. 2023 ($56,777.90 Mil) to Dec. 2023 ($56,827.70 Mil) and increased from Dec. 2023 ($56,827.70 Mil) to Jun. 2024 ($61,095.80 Mil).

Sanofi's annual Total Liabilities declined from Dec. 2021 ($57,865.54 Mil) to Dec. 2022 ($54,629.24 Mil) but then increased from Dec. 2022 ($54,629.24 Mil) to Dec. 2023 ($56,827.70 Mil).

Sanofi Total Liabilities Historical Data

The historical data trend for Sanofi's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Total Liabilities Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

59,333.33

62,300.49

57,865.54

54,629.24

56,827.70

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial															53,405.92	54,629.24	56,777.90	56,827.70	61,095.80

Sanofi Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sanofi's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26398.037	+	(17559.433	+	10845.147
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2025.082	+	0)
	=	56,828

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	137910.578	-	81082.879
	=	56,828

Sanofi's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32321.851	+	(15324.004	+	11512.38
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1937.567	+	0)
	=	61,096

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	139671.69	-	78575.888
	=	61,096

Sanofi Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sanofi's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SNY:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.